Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Efficacy of velaglucerase alfa treatment evaluated over 7 years

Feb. 22, 2013

FDA recommends phase III Androxal studies to be completed as planned

Feb. 22, 2013

Canadian university researchers synthesize novel inhibitors of ABHD6

Feb. 22, 2013

New estrogen receptor ligands reported by Karo Bio

Feb. 21, 2013

New androgen receptor agonists divulged by Novartis

Feb. 19, 2013

FDA accepts lixisenatide NDA for review

Feb. 19, 2013

FDA grants orphan drug status to diabetes vaccine candidate

Feb. 19, 2013

Idursulfase beta gains orphan drug status in U.S.

Feb. 19, 2013

FDA grants orphan drug status to SOV's testosterone undecanoate

Feb. 19, 2013

Livalo OD tablets approved in Japan for hypercholesteremia

Feb. 18, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...